PLURISTEM THERAPEUTICS INC (PSTI) Stock Price, Quote, News and Overview
NASDAQ:PSTI - Nasdaq - US72940R3003 - Common Stock - Currency: USD
PSTI Quote, Performance and Key Statistics
1
-0.03 (-2.91%)
The current stock price of PSTI is 1 USD. In the past month the price decreased by -21.26%. In the past year, price decreased by -69.51%.
PSTI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.77 | 322.91B | ||
| AMGN | AMGEN INC | 13.1 | 146.19B | ||
| GILD | GILEAD SCIENCES INC | 13.79 | 132.89B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.58B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.47 | 64.44B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.59B | ||
| ARGX | ARGENX SE - ADR | 99.05 | 35.50B | ||
| ONC | BEIGENE LTD-ADR | 5.93 | 25.74B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.82B | ||
| NTRA | NATERA INC | N/A | 20.73B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.14B | ||
| BIIB | BIOGEN INC | 7.98 | 18.51B |
Related stock screener links
About PSTI
Company Profile
Pluristem Therapeutics, Inc. is a clinical stage company, which engages in cell therapy development. The firm's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The firm's products include PLX-PAD and PLX R18. The firm's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The firm's PLX products are administered using a standard needle and syringe. The firm's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.
Company Info
PLURISTEM THERAPEUTICS INC
Building No. 5, Matam Advanced Technology Park
Haifa 3508409 IL
CEO: Yaky Yanay
Employees: 129
Phone: 972747107171.0
PLURISTEM THERAPEUTICS INC / PSTI FAQ
What is the stock price of PLURISTEM THERAPEUTICS INC today?
The current stock price of PSTI is 1 USD. The price decreased by -2.91% in the last trading session.
What is the ticker symbol for PLURISTEM THERAPEUTICS INC stock?
The exchange symbol of PLURISTEM THERAPEUTICS INC is PSTI and it is listed on the Nasdaq exchange.
On which exchange is PSTI stock listed?
PSTI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PLURISTEM THERAPEUTICS INC stock?
8 analysts have analysed PSTI and the average price target is 3.57 USD. This implies a price increase of 257% is expected in the next year compared to the current price of 1. Check the PLURISTEM THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PLURISTEM THERAPEUTICS INC worth?
PLURISTEM THERAPEUTICS INC (PSTI) has a market capitalization of 32.35M USD. This makes PSTI a Nano Cap stock.
How many employees does PLURISTEM THERAPEUTICS INC have?
PLURISTEM THERAPEUTICS INC (PSTI) currently has 129 employees.
What are the support and resistance levels for PLURISTEM THERAPEUTICS INC (PSTI) stock?
PLURISTEM THERAPEUTICS INC (PSTI) has a resistance level at 1.04. Check the full technical report for a detailed analysis of PSTI support and resistance levels.
Should I buy PLURISTEM THERAPEUTICS INC (PSTI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PSTI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PSTI, evaluating the profitability, health, valuation and growth aspects
- PLURISTEM THERAPEUTICS INC (PSTI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PLURISTEM THERAPEUTICS INC (PSTI) Sales and EPS estimates to see what analysts future expectations are.
- PLURISTEM THERAPEUTICS INC (PSTI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PLURISTEM THERAPEUTICS INC (PSTI) Insider and Institutional Ownership to learn about the owners and their transactions.
- PLURISTEM THERAPEUTICS INC (PSTI) Stock Chart to make your own analysis
- PLURISTEM THERAPEUTICS INC (PSTI) Latest news and press-releases to stay up to date.
Does PLURISTEM THERAPEUTICS INC (PSTI) stock pay dividends?
PSTI does not pay a dividend.
What is the Price/Earnings (PE) ratio of PLURISTEM THERAPEUTICS INC (PSTI)?
PLURISTEM THERAPEUTICS INC (PSTI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.47).
PSTI Technical Analysis
PSTI Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to PSTI. PSTI has an excellent profitability rating, but there are some minor concerns on its financial health.
PSTI Financial Highlights
Over the last trailing twelve months PSTI reported a non-GAAP Earnings per Share(EPS) of -1.47. The EPS increased by 9.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20373.91% | ||
| ROA | 59.22% | ||
| ROE | 123.02% | ||
| Debt/Equity | 0.6 |
PSTI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to PSTI. The Buy consensus is the average rating of analysts ratings from 8 analysts.